Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
The gene p53 encodes a transcriptional activator of genes involved in growth arrest, DNA repair and apoptosis. Loss of p53 function contributes to tumour development in vivo. The transcriptional activation function of p53 is inactivated by interaction with the mdm2 gene product. Amplification of mdm2 has been observed in 36% of human sarcomas, indicating that it may represent an alternative mechanism of preventing p53 function in tumour development. To study mdm2 function in vivo, we generated an mdm2 null allele by homologous recombination. Mdm2 null mice are not viable, and further analysis revealed embryonic lethality around implantation. To examine the importance of the interaction of MDM2 with p53 in vivo, we crossed mice heterozygous for mdm2 and p53 and obtained progeny homozygous for both p53 and mdm2 null alleles. Rescue of the mdm2-/- lethality in a p53 null background suggests that a critical in vivo function of MDM2 is the negative regulation of p53 activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mdm2 can recruit HDAC1 to p53 to remove these acetylation marks and allow for p53 ubiquitination and degradation [49] in in vitro and mouse models [47,50].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [50]
In the citing paper
“Loss of Mdm2 leads to cell death by apoptosis and embryonic lethality at the blastocyst stage, and this phenotype is completely rescued by concomitant deletion of p53 (Chavez-Reyes, et al., 2003; Jones, et al., 1995; Montes de Oca Luna, et al., 1995).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Montes de Oca Luna, et al., 1995
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [107]
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108 and that they exert non-overlapping inhibitory activities towards p53 (Refs 24,109).”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [107]
In the citing paper
“The crucial importance of MDM2 in regulating p53 was demonstrated using Mdm2-null mice, which display very early embryonic lethality (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
From p53 at a glance (2010) · cites this paper as Montes de Oca Luna et al., 1995
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Thymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
Research works printed but not linked: 1
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 601–700 of 1,001
Forslund, A., Zeng, Z., Qin, L.-X., Rosenberg, S., Ndubuisi, M., Pincas, H., Gerald, W., Notterman, D. A., Barany, F., & Paty, P. B. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0239 · Cited by 54
“The lethal phenotype of MDM2 knockout mice is completely overcome by concomitant inactivation of the p53 gene (3).”
BackgroundDeubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1
Sun, X., & Dai, M.-S. (2014) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v5.i2.75 · Cited by 60
Regulation of hematopoietic stem cell fate by the ubiquitin proteasome system
Moran-Crusio, K., Reavie, L. B., & Aifantis, I. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.01.009 · Cited by 58
Regulation of stem cell function by protein ubiquitylation
Strikoudis, A., Guillamot, M., & Aifantis, I. (2014) · EMBO Reports · doi:10.1002/embr.201338373 · Cited by 62
“Several studies have demonstrated that this is a cellintrinsic effect alleviated by p53 downregulation or treatment with antioxidants [111, 112].”
p53 orchestrates between normal differentiation and cancer
Rivlin, N., Koifman, G., & Rotter, V. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.006 · Cited by 62
Danilova, N., Sakamoto, K. M., & Lin, S. (2008) · Mechanisms of Development · doi:10.1016/j.mod.2008.09.003 · Cited by 65
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer
de Oliveira, G. A. P., Rangel, L. P., Costa, D. C., & Silva, J. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00097 · Cited by 53
“The p53–Mdm2 interaction has been shown to be critical when the lethality of mdm2-null mice was rescued by simultaneous deletion of the TP53 gene (87, 88).”
BackgroundClement, J. A., Kitagaki, J., Yang, Y., Saucedo, C. J., O’Keefe, B. R., Weissman, A. M., McKee, T. C., & McMahon, J. B. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.024 · Cited by 55
Regulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo
Jackson, J. G., Post, S. M., & Lozano, G. (2011) · The Journal of Pathology · doi:10.1002/path.2783 · Cited by 53
Self-citationHafsi, H., & Hainaut, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3771 · Cited by 53
Hayano, S., Komatsu, Y., Pan, H., & Mishina, Y. M. (2015) · Development · doi:10.1242/dev.118802 · Cited by 56
“Among several E3 ligases, MDM2 is identified as a key E3 ligase in the p53 regulatory network (Montes de Oca Luna et al., 1995).”
BackgroundModifications of p53: competing for the lysines
Carter, S. A., & Vousden, K. H. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.11.010 · Cited by 72
A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2
Wang, J., He, X., Luo, Y., & Yarbrough, W. G. (2005) · Biochemical Journal · doi:10.1042/bj20050960 · Cited by 54
The vaccinia virus B1R kinase induces p53 downregulation by an Mdm2-dependent mechanism
Santos, C. R., Vega, F. M. D. L., Blanco, S., Barcia, R., & Lazo, P. A. (2004) · Virology · doi:10.1016/j.virol.2004.08.013 · Cited by 57
Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development
Steinman, H. A., Hoover, K. L., Keeler, M. L., Sands, A., & Jones, S. N. (2005) · Oncogene · doi:10.1038/sj.onc.1208930 · Cited by 60
“Furthermore, deletion of Bax, but not p21, has been reported to modestly delay the embryonic lethality of Mdm2 null embryos (Montes de Oca Luna et al., 1997; Chavez-Reyes et al., 2003), whereas deletion of p21 partially rescues Mdm4 null mice (Steinman et al., 2004).”
Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma
Cissé, M. Y., Pyrdziak, S., Firmin, N., Gayte, L., Heuillet, M., Bellvert, F., Fuentes, M., Delpech, H., Riscal, R., Arena, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay2163 · Cited by 54
Inactivation of arf-bp1 Induces p53 Activation and Diabetic Phenotypes in Mice
Kon, N., Zhong, J., Qiang, L., Accili, D., & Gu, W. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.322867 · Cited by 52
Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation
Hallenborg, P., Feddersen, S., Francoz, S., Murano, I., Sundekilde, U. K., Petersen, R. K., Akimov, V., Olson, M. V., Lozano, G., Cinti, S., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.15 · Cited by 51
“of p53 activity is underscored by the finding that knockout of p53 rescues the embryonic lethality of mice lacking mdm2.(10,11) Deregulation of p53 activity in embryos lacking mdm2 leads to widespread apoptosis and ensuing embryonic death.”
BackgroundSelf-citationReinke, V., & Lozano, G. (1997) · Radiation Research · doi:10.2307/3579567 · Cited by 58
Self-citationTargeting the ubiquitin–proteasome system to activate wild-type p53 for cancer therapy
Allende-Vega, N., & Saville, M. K. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.004 · Cited by 52
Leslie, P. L., Ke, H., & Zhang, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.644435 · Cited by 54
Proteasome‐mediated proteostasis: Novel medicinal and pharmacological strategies for diseases
Mishra, R., Upadhyay, A., Prajapati, V. K., & Mishra, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21502 · Cited by 51
Culture of Zygotes Increases p53 Expression in B6 Mouse Embryos, which Reduces Embryo Viability1
Li, A., Chandrakanthan, V., Chami, O., & O’Neill, C. (2006) · Biology of Reproduction · doi:10.1095/biolreprod.106.056838 · Cited by 50
“The preimplantation embryo lethality of Mdm2 / embryos is reversed by the double-knockout Mdm2 / Trp53 / [16, 17], suggesting that the loss of TRP53 latency via reduced MDM2 is a plausible cause of the increased TRP53 expression of embryos following culture.”
BackgroundA Glance of p53 Functions in Brain Development, Neural Stem Cells, and Brain Cancer
Xiong, Y., Zhang, Y., Xiong, S., & Williams-Villalobo, A. (2020) · Biology · doi:10.3390/biology9090285 · Cited by 59
“Mdm2 null mice exhibited early embryonic lethality, a phenotype that can b readily rescu d by deletion of p53, indicating the ti ht regulation of p53 activity uring normal embryonic development [11].”
BackgroundRegulation of MDM2 Stability After DNA Damage
Li, J., & Kurokawa, M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24994 · Cited by 54
Targeting the MDM2/MDM4 Interaction Interface as a Promising Approach for p53 Reactivation Therapy
Pellegrino, M., Mancini, F., Lucà, R., Coletti, A., Giacchè, N., Manni, I., Arisi, I., Florenzano, F., Teveroni, E., Buttarelli, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0439 · Cited by 56
“Since the discovery of MDM2 as crucial p53 inhibitor (3,4), there have been numerous attempts to pharmacologically disrupt the interaction between these two proteins in order to reactivate p53 in human wild-type TP53 tumors (2).”
BackgroundRecent Advances in Validating MDM2 as a Cancer Target
Rayburn, E. R., Ezell, S. J., & Zhang, R. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009789124628 · Cited by 54
Therapeutic Targets in the ARF Tumor Suppressor Pathway
Saporita, A. J., Maggi, L. B., Apicelli, A. J., & Weber, J. D. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707781058869 · Cited by 60
Do we need more drugs for chronic myeloid leukemia?
Holyoake, T. L., & Helgason, G. V. (2014) · Immunological Reviews · doi:10.1111/imr.12234 · Cited by 53
Systems biology analysis reveals role of MDM2 in diabetic nephropathy
Saito, R., Arjó, A. R., You, Y.-H., Darshi, M., Espen, B. V., Miyamoto, S., Pham, J., Pu, M., Romoli, S., Natarajan, L., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87877 · Cited by 51
Haraguchi, H., Hirota, Y., Saito‐Fujita, T., Tanaka, T., Shimizu‐Hirota, R., Harada, M., Akaeda, S., Hiraoka, T., Matsuo, M., Matsumoto, L., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201801401r · Cited by 52
MDM2 expression is repressed by the RNA-binding protein RNPC1 via mRNA stability
Xu, E., Zhang, J., & Chen, X. (2012) · Oncogene · doi:10.1038/onc.2012.238 · Cited by 51
New insights into 5q- syndrome as a ribosomopathy
Barlow, J. L., Drynan, L. F., Trim, N., Erber, W. N., Warren, A. J., & McKenzie, A. N. J. (2010) · Cell Cycle · doi:10.4161/cc.9.21.13742 · Cited by 51
Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis
Moore, L., Venkatachalam, S., Vogel, H., Watt, J. C., Wu, C.-L., Steinman, H., Jones, S. N., & Donehower, L. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206985 · Cited by 48
“The primary role of Mdm2 during development is to modulate p53 activity, since the absence of Mdm2 in the mouse leads to embryonic lethality, which can be rescued by removal of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
BackgroundBH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death
Wade, M., Rodewald, L. W., Espinosa, J. M., & Wahl, G. M. (2008) · Cell Cycle · doi:10.4161/cc.7.13.6072 · Cited by 48
MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53
Klein, A. M., Biderman, L., Tong, D., Alaghebandan, B., Plumber, S. A., Mueller, H. S., van Vlimmeren, A. E., Katz, C., & Prives, C. L. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102420118 · Cited by 50
Casein Kinase 1 α Regulates an MDMX Intramolecular Interaction To Stimulate p53 Binding
Wu, S., Chen, L., Becker, A., Schonbrunn, E., & Chen, J. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00851-12 · Cited by 47
“Genetic analyses showed that both MDM2 and MDMX are essential for controlling p53 activity during embryogenesis (17, 35, 38).”
BackgroundmicroRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis
Zhang, C., Liu, J., Tan, C., Yue, X., Zhao, Y., Peng, J., Wang, X., Laddha, S. V., Chan, C. S., Zheng, S. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7088 · Cited by 51
“MDM2 is the most critical negative regulator for p53, which has been clearly demonstrated by the embryonic lethality caused by MDM2 knockout in mice that can be rescued by p53 knockout [43, 44].”
BackgroundCui, R., Nguyen, T. T. T., Taube, J. H., Stratton, S. A., Feuerman, M. H., & Barton, M. C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504655200 · Cited by 51
Genetic modeling of Li-Fraumeni syndrome in zebrafish
Parant, J. M., George, S. A., Holden, J. A., & Yost, H. J. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.003749 · Cited by 49
“…are remnants of functionality in mutant p53 proteins in multiple tissues and pathways, including apoptosis, cell cycle arrest, and others (Chavez-Reyes et al., 2003; Iwakuma et al., 2004; Jones et al., 1995; Lang et al., 2004; Liu et al., 2007; Montes de Oca Luna et al., 1995; Toledo et al., 2006).”
BackgroundFeedback Control of p53 Translation by REDD1 and mTORC1 Limits the p53-Dependent DNA Damage Response
Vadysirisack, D. D., Baenke, F., Ory, B., Lei, K., & Ellisen, L. W. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05541-11 · Cited by 56
“Unlike Mdm2 / mice, which die early in embryogenesis due to p53-dependent apoptosis, we find that Redd1 / mice are viable and fertile (6, 23).”
BackgroundJin, X., Chandrakanthan, V., Morgan, H. D., & O’Neill, C. (2008) · Biology of Reproduction · doi:10.1095/biolreprod.108.070102 · Cited by 47
“Absence of MDM2 (Mdm2 / ) in the preimplantation embryo results in their death, while a simultaneous lack of TRP53 (Mdm2 / Trp53 / compound mutant) rescues embryos from this lethality [22, 23].”
BackgroundResultSayin, V. I., Khan, O. M., Pehlivanoglu, L. E., Staffas, A., Ibrahim, M. X., Asplund, A., Ågren, P., Nilton, A., Bergström, G. M. L., Bergö, M. O., et al. (2014) · Circulation Research · doi:10.1161/circresaha.115.304992 · Cited by 48
“Activation of p53 in the endothelium, for example, leads to endothelial dysfunction and atherosclerosis,46–48 and global activation of p53 is lethal as shown by knockouts of the p53inhibitor Mdm2.”
BackgroundRole of Mdm2 and Mdmx in DNA repair
Eischen, C. M. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw052 · Cited by 45
“Genetic studies with knockout mice have firmly established that Mdm2 and Mdmx regulate the tumour suppressor p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995; Parant et al., 2001; Finch et al., 2002; Migliorini et al., 2002).”
BackgroundMoyer, S. M., Wasylishen, A. R., Qi, Y., Fowlkes, N. W., Su, X., & Lozano, G. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008474117 · Cited by 48
“Mdm2-null and Mdm4-null mice are embryonic lethal indicating that Mdm proteins are vital in development (33-35).”
BackgroundSelf-citationThe Nuclear Pore Complex and mRNA Export in Cancer
Borden, K. L. B. (2020) · Cancers · doi:10.3390/cancers13010042 · Cited by 54
Mdm2 and Tumorigenesis: Evolving Theories and Unsolved Mysteries
Senturk, E., & Manfredi, J. J. (2012) · Genes & Cancer · doi:10.1177/1947601912457368 · Cited by 51
“The importance of this interplay, at least from a development standpoint, is evidenced by the finding that MDM2 mice die early in embryonic development but are rescued in a p53 background.(17,18) These and additional data from human tumors collectively support an oncogenically relevant role for Mdm2 that rests on its…”
BackgroundOf flies and men; p53, a tumour suppressor
Sutcliffe, J. E., & Brehm, A. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.03.122 · Cited by 46
“cells, and reducing the level of p53 in stressed cells, once the damage has been repaired [8,9].”
BackgroundSenescent cells limit p53 activity via multiple mechanisms to remain viable
Sturmlechner, I., Sine, C. C., Jeganathan, K. B., Zhang, C., Fierro Velasco, R. O., Baker, D. J., Li, H., & van Deursen, J. M. (2022) · Nature Communications · doi:10.1038/s41467-022-31239-x · Cited by 45
Modelling the onset of senescence at the G1/S cell cycle checkpoint
Mombach, J. C., Bugs, C. A., & Chaouiya, C. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-s7-s7 · Cited by 45
“Mdm2 No damage: proliferation With damage: apoptosis Apoptosis [45]”
BackgroundInfluentialZeng, Z., Richardson, J., Verduzco, D., Mitchell, D. L., & Patton, E. E. (2009) · Zebrafish · doi:10.1089/zeb.2009.0611 · Cited by 53
Survival signaling in the preimplantation embryo
O’Neill, C., Li, Y., & Jin, X. (2012) · Theriogenology · doi:10.1016/j.theriogenology.2011.12.016 · Cited by 52
Han, X., Garcia‐Manero, G., McDonnell, T. J., Lozano, G., Medeiros, L. J., Xiao, L., Rosner, G. L., Nguyen, M. H., Fernandez, M., Valentin-Vega, Y. A., et al. (2006) · Modern Pathology · doi:10.1038/modpathol.3800727 · Cited by 48
Self-citationInterferon-Inducible Protein IFIXα1 Functions as a Negative Regulator of HDM2
Ding, Y., Lee, J.-F., Lu, H., Lee, M.-H., & Yan, D.-H. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.5.1979-1996.2006 · Cited by 45
Function and dysfunction of the human oncoprotein MDM2
Deb, S. P. (2002) · Frontiers in bioscience · doi:10.2741/a723 · Cited by 50
“The p53-regulatory function of MDM2 is required for embryonic development (67, 68).”
BackgroundAbnormalities of developmental cell death in Dad1‐deficient mice
Nishii, K., Tsuzuki, T., Kumai, M., Takeda, N., Koga, H., Aizawa, S., Nishimoto, T., & Shibata, Y. (1999) · Genes to Cells · doi:10.1046/j.1365-2443.1999.00256.x · Cited by 47
Jabbur, J. R., Tabor, A., Cheng, X., Wang, H., Uesugi, M., Lozano, G., & Zhang, W. (2002) · Oncogene · doi:10.1038/sj.onc.1205856 · Cited by 52
“To further our understanding of the influence of Mdm-2 on p53 transactivation in response to hydrogen bond disruption between the p53 residues Thr18 and Asp21, we examined the transactivation potential for p21 mediated by wt p53 and hydrogen bond disrupting or retaining p53 mutants in the p53/Mdm-2 double-null cell li…”
BackgroundSelf-citationEngineered extrachromosomal oncogene amplifications promote tumorigenesis
Pradella, D., Zhang, M., Gao, R., Yao, M. A., Głuchowska, K., Cendón, Y., Mishra, T., Rocca, G. L., Weigl, M., Jiao, Z., et al. (2024) · Nature · doi:10.1038/s41586-024-08318-8 · Cited by 65
Wienken, M., Moll, U. M., & Dobbelstein, M. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw046 · Cited by 49
“The mechanistic reasons are unknown (Montes de Oca Luna et al., 1995).”
InfluentialMutant p53 establishes targetable tumor dependency by promoting unscheduled replication
Singh, S., Vaughan, C. A., Frum, R. A., Grossman, S. R., Deb, S., & Deb, S. P. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87724 · Cited by 49
Phosphatidylinositol 3-kinase signaling in mammalian preimplantation embryo development
O’Neill, C. (2008) · Reproduction · doi:10.1530/rep-08-0105 · Cited by 46
Stabilization and Activation of p53 by the Coactivator Protein TAFII31
Buschmann, T., Lin, Y., Aithmitti, N., Fuchs, S. Y., Lu, H., Resnick‐Silverman, L., Manfredi, J. J., Ronai, Z. A., & Wu, X. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007955200 · Cited by 54
The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies
Cox, D. G., Deer, D., Guo, Q., Tworoger, S. S., Hankinson, S. E., Hunter, D. J., & Vivo, I. D. (2007) · Cancer Causes & Control · doi:10.1007/s10552-007-9004-x · Cited by 46
“mouse embryos die in utero before implantation, and this lethal phenotype can be reversed by knocking out p53 [27, 28].”
BackgroundDisruptingTP53 in mouse models of human cancers
Parant, J. M., & Lozano, G. (2003) · Human Mutation · doi:10.1002/humu.10186 · Cited by 44
Self-citationMultiple Murine Double Minute Gene 2 (MDM2) Proteins Are Induced by Ultraviolet Light
Saucedo, L. J., Myers, C. D., & Perry, M. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8161 · Cited by 55
Tunneling nanotube (TNT) formation is independent of p53 expression
Andresen, V., Wang, X., Ghimire, S., Omsland, M., Gjertsen, B. T., & Gerdes, H. H. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.61 · Cited by 46
Transgenic and Knockout Mice Models to Reveal the Functions of Tumor Suppressor Genes
Taneja, P., Zhu, S., Maglic, D., Fry, E. A., Kendig, R. D., & Inoue, K. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7516 · Cited by 50
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
Chen, L., & Tweddle, D. A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00173 · Cited by 47
“This is supported by the observed embryonic lethality of MDM2 knockout mice and their rescue by the concomitant deletion of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
Wang, M., Zhang, Z., Zhu, H., Fu, G., Wang, S., Wu, D., Zhou, J., Wei, Q., & Zhang, Z. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5155 · Cited by 44
Mechanisms of suppression: The wiring of genetic resilience
van Leeuwen, J. S., Pons, C., Boone, C. M., & Andrews, B. (2017) · BioEssays · doi:10.1002/bies.201700042 · Cited by 51
“For example, the embryonic lethality caused by loss ofMdm2, which encodes a negative regulator of the cell cycle arrest-inducing protein p53, can be suppressed by loss of p53 in mice [38, 39].”
Hauck, L., Stanley-Hasnain, S., Fung, A., Grothe, D., Rao, V., Mak, T. W., & Billia, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189861 · Cited by 48
Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein.
Węsierska‐Gądek, J., & Schmid, G. (2001) · PubMed · Cited by 48
Suppression of p53 activity by Siva1
Du, W., Jiang, P., Li, N., Mei, Y., Wang, X., Wen, L., Yang, X., & Wu, M. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.89 · Cited by 49
“observation that the early embryonic lethality in mice with Mdm2 deficiency can be completely rescued by simultaneous inactivation of p53.(6,7) Mdm2 is itself an unstable protein, and”
Animal models of melanoma: Recent advances and future prospects
Bardeesy, N. M., Wong, K., DePinho, R. A., & Chin, L. (2000) · Advances in cancer research · doi:10.1016/s0065-230x(00)79004-x · Cited by 47
p14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts
Khan, S. H., Guevara, C. I., Fujii, G., & Parry, D. (2004) · Oncogene · doi:10.1038/sj.onc.1207824 · Cited by 55
“The major target of MDM2 is p53, as demonstrated by embryonic lethality of MDM2 nullizygous mice, a phenotype rescued by inactivating p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
BackgroundStructural and Functional Comparison of the RING Domains of Two p53 E3 Ligases, Mdm2 and Pirh2
Shloush, J., Vlassov, J. E., Engson, I., Duan, S., Saridakis, V., Dhe-paganon, S., Raught, B., Sheng, Y., & Arrowsmith, C. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.157669 · Cited by 42
Li, X., Gohain, N., Chen, S., Li, Y., Zhao, X., Li, B., Tolbert, W. D., He, W., Pazgier, M., Hu, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.010 · Cited by 42
Tissue‐specific and age‐dependent effects of global Mdm2 loss
Zhang, Y., Xiong, S., Li, Q., Hu, S., Tashakori, M., Van Pelt, C., You, M. J., Pageon, L., & Lozano, G. (2014) · The Journal of Pathology · doi:10.1002/path.4368 · Cited by 42
“Mdm2 is required for embryonic development, since germline deletion of Mdm2 is embryonic lethal, due to p53-induced apoptosis [2,3].”
BackgroundSelf-citationA p53-Pax2 Pathway in Kidney Development: Implications for Nephrogenesis
Saifudeen, Z. R., Liu, J., Dipp, S., Yao, X., Li, Y., McLaughlin, N., Aboudehen, K., & El-Dahr, S. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044869 · Cited by 49
“In contrast, excess p53 activity, achieved by deletion of its negative regulator MDM2, results in embryonic death at peri-implantation stage that can be rescued by p53 deletion [46].”
BackgroundG2E3 is a nucleo-cytoplasmic shuttling protein with DNA damage responsive localization
Brooks, W. S., Banerjee, S., & Crawford, D. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.11.020 · Cited by 47
“Early embryonic lethality is also observed when several other genes involved in the DNA damage response are inactivated [46-53].”
BackgroundMalek, R. A., Matta, J. L., Taylor, N. E., Perry, M. E., & Mendrysa, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017884 · Cited by 53
MDM2 mediates p73 ubiquitination: a new molecular mechanism for suppression of p73 function
Wu, H., & Leng, R. P. (2015) · Oncotarget · doi:10.18632/oncotarget.4086 · Cited by 48
“The deletion of Mdm2 in mice results in an embryonic lethal phenotype, but lethality can be prevented by deletion of the p53 gene, indicating the importance of the negative regulatory function of Mdm2 on p53 during development [16, 17].”
Cell Survival Signaling in Neuroblastoma
Megison, M. L., Gillory, L. A., & Beierle, E. A. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313040005 · Cited by 49
MDM2 expression during mouse embryogenesis and the requirement of p53
Léveillard, T., Gorry, P., Niederreither, K., & Wasylyk, B. (1998) · Mechanisms of Development · doi:10.1016/s0925-4773(98)00074-4 · Cited by 43
Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53–HDM2 Protein–Protein Interaction
Fischer, P. M. (2006) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-006-9016-5 · Cited by 42
“It could be argued that attenuation of HDM2 might result in promiscuous toxicity on the basis that MDM2 (mouse double minute 2) knock-out mice are not viable (Montes de Oca Luna et al., 1995).”
BackgroundEffects of theMDM2promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk
Knappskog, S., & Lønning, P. E. (2011) · Transcription · doi:10.4161/trns.2.5.16813 · Cited by 44
“The functional importance of this balanced interaction is illustrated by the findings that knock-out of the MDM2 gene leads to embryonic lethality in mice, an effect rescued by concomitant p53 deletion.(4,5) In addition to the tight link to p53, MDM2 is also known to interact with several other major players involved…”
BackgroundAndreotti, V., Ciribilli, Y., Monti, P., Bisio, A., Lion, M., Jordan, J., Fronza, G., Menichini, P., Resnick, M. A., & Inga, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020643 · Cited by 57
Mdm proteins: critical regulators of embryogenesis and homoeostasis
Moyer, S. M., Larsson, C. A., & Lozano, G. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx004 · Cited by 41
“The loss of Mdm2 in an embryo results in death due to a p53mediated apoptotic mechanism (Jones et al., 1995; ChavezReyes et al., 2003; Montes de Oca Luna et al., 1995; Parant et al., 2001).”
BackgroundSelf-citationThe Role of MDM2 in Promoting Genome Stability versus Instability
Saadatzadeh, M., Elmi, A., Pandya, P., Bijangi-Vishehsaraei, K., Ding, J., Stamatkin, C., Cohen-Gadol, A., & Pollok, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102216 · Cited by 41
“However, lethality in MDM2 gene knock out mice can be reversed by co-deletion of the p53 gene, further emphasizing how an imbalance of MDM2 and p53 can dramatically affect survival at the cellular and organism levels [64,65].”
BackgroundCompetitive ubiquitination activates the tumor suppressor p53
Li, X., Guo, M., Cai, L., Du, T., Liu, Y., Ding, H., Wang, H., Zhang, J., Chen, X., & Yan, C. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0463-x · Cited by 42
“The crucial role of MDM2 in the regulation of p53 activity is supported by the observations that knockout (KO) of the Trp53 gene rescues mouse embryonic lethality caused by Mdm2 loss [6, 7], and that overexpression of MDM2, or its homolog MDMX, frequently occurs in human cancers not harboring TP53 mutations [8].”
BackgroundMK2 regulates the early stages of skin tumor promotion
Johansen, C., Vestergaard, C., Kragballe, K., Kollias, G. A., Gaestel, M., & Iversen, L. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp238 · Cited by 44
Kinetic Partitioning During Folding of the p53 DNA Binding Domain
Butler, J. S., & Loh, S. N. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.05.060 · Cited by 41
p53 and p53 ‐regulated genes in bladder cancer
Keegan, Lunec, & Neal, D. E. (1998) · British Journal of Urology · doi:10.1046/j.1464-410x.1998.00822.x · Cited by 42
Jeong, P., Yoon, S., Choi, S., Song, B., Kim, J.-S., Sim, B., Park, Y., Yang, H.-J., Mun, S.-E., Kim, Y., et al. (2016) · Reproduction Fertility and Development · doi:10.1071/rd15391 · Cited by 42
Humpton, T. J., Hall, H., Kiourtis, C., Nixon, C., Clark, W. A., Hedley, A., Shaw, R., Bird, T. G., Blyth, K., & Vousden, K. H. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00871-3 · Cited by 47
Anatomy of Mdm2 and Mdm4 in evolution
Tan, B. X., Liew, H. P., Chua, J. S., Ghadessy, F. J., Tan, Y. S., Lane, D. P., & Coffill, C. R. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx002 · Cited by 35
“Gene-specific morpholino oligonucleotides (MO) are commonly injected into zebrafish embryos to transiently suppress gene expression (Nasevicius and Ekker, 2000).”
MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation In Vivo
Yang, J., Jin, A., Han, J., Chen, X., Zheng, J., & Zhang, Y. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0790 · Cited by 44
“Deletion ofMDM2 inmice causes increase in p53 protein levels and transcriptional activity and induces embryonic lethality; and the lethality can be rescued by co-deletion of p53, demonstrating that a primary function of MDM2, at least during mouse embryogenesis, is to keep p53 at low levels and inactive (4, 5).”
Węsierska‐Gądek, J., & HORKYA, M. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1299.046 · Cited by 40
MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase varepsilon
Vlatkovic, N. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.18.3581 · Cited by 40
Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo
Xiong, S., Chachad, D., Zhang, Y., Gencel-Augusto, J., Sirito, M., Pant, V., Yang, P., Sun, C., Chau, G., Qi, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3376 · Cited by 44
Self-citation
Metadata
- Authors
- de Oca Luna, R. M., Wagner, D. S., & Lozano, G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Venue
- Nature
- Published
- 1995-11
- Volume
- 378
- Issue
- 6553
- Pages
- 203-206
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1969044026
- Semantic Scholar
- e682601f6b2b8de8fa63cc39518a1461943483bc
- Cited by
- 1,420
- References
- 29
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 31 · 2023: 30 · 2022: 31 · 2021: 32 · 2020: 49 · 2019: 29 · 2018: 32 · 2017: 49 · 2016: 63 · 2015: 44 · 2014: 67 · 2013: 37 · 2012: 63
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, MDM2, embryonic lethality, p53-MDM2 interaction, tumor suppressor, sarcoma, homologous recombination, DNA repair
- MeSH terms
- Animals, Base Sequence, Cell Line, Crosses, Genetic, Female, Genes, Lethal, Heterozygote, Homozygote, Male, Mice, Inbred C57BL, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Gene Deletion, DNA Primers, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.